PRKACA

Across TCGA pan-cancer cohorts, PRKACA mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRKACA data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PRKACA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRKACA expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where PRKACA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.383	1.000	.020	18	view →
LUAD	DFS	Tertile	All	0.780	0.515	.012	12	view →
CCRCC	OS	Tertile	All	0.960	0.698	.003	10	view →
HNSC	DFS	Tertile	II,III,IV	0.886	0.988	.012	10	view →
PDAC	OS	Median	All	0.586	0.395	.027	2	view →
GBM	OS	Median	All	0.893	0.735	.040	1	view →
LSCC	DFS	Median	All	0.929	0.615	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRKACA–UCEC (DFS)

Open the UCEC breakdown →